drugset / Trial / NCT00660725
Study of GemOx and Vandetanib in Advanced Solid Malignancy
NaSingle-groupOpen-labelTreatment
Summary
This is a research study that will try to find the highest and safest dose of an experimental drug, vandetanib, that can be given in combination with two standard chemotherapy agents, gemcitabine and oxaliplatin, to subjects with advanced solid malignancies.
Timeline
- Start
- 2009-02
- Primary completion
- 2010-11
- Completion
- 2010-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vandetanib | Small molecule | 200 mg | Oral |
| Subject | Vandetanib | Small molecule | 300 mg | Oral |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Background | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |